Europe’s Digital Health Path Still at a Crossroads

In this ISSUE

How AI, Wearables, and Translational Informatics Are Changing Healthcare

Keeping Up with Compliance in Labeling

Marketing: Being More Human Doesn't Mean Being Less Transparent

Top Story

Europe's Digital Health Path Still at a Crossroads

The Commission's gestures toward enacting formal standards to digitize health records are masking wider policy gaps. Reflector reports.
… /Read more/

TECHNOLOGY

Lessons for Pharma from the Merck Cyber Attack

Almost a year and a half on, key understandings have emerged to help companies better combat future data-breach attempts. Chris Souza reports.
… /Read more/

Q&A

Rajiv Malik, President, Mylan

Mylan President Rajiv Malik talks about what progresses society has made in the fight against HIV, what challenges companies face in tackling medicine delivery to developing countries, and bringing those innovations back to the US and Europe
… /Read more/

Patient Assistance Centers of Excellence: The Next Generation of Brand Support
On Demand

Learn More

Regulatory Affairs

5 Ways to Shape a Regulatory Affairs Workforce for the Future

Pharmaceutical regulatory divisions should use the same discipline, rigor and focus on the talent pipeline as they do the product pipeline, writes Karin Van Baelen
… /Read more/

Biotech

Trust–Biotech's Hidden Advantage

Bruce Hayes discusses how companies can build trust now to cultivate corporate reputations that build business
… /Read More/

Calendar

/ January 22–23, 2019: 14^th Biosimilars Summit /

Alexandria, VA

/ January 23–24, 2019: Data Analytics and Decisions /

Philadelphia, PA

/ January 24–25, 2019: Specialty Therapies 2019 /

Las Vegas, NV

/ January 29–30, 2019: 6^th Annual Clinical Data Disclosure and Transparency /

Philadelphia, PA

/ February 4–5, 2019: Disease Awareness Campaigns /

Philadelphia, PA

/ March 4–6, 2019: 20th Annual Patient Assistance and Access Programs – PAP 2019 /

Baltimore, MD

/ March 12–13, 2019: Pharmaceutical Compliance Congress Asia /

Shanghai, China

Industry update

// The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) elected David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly and Company, as new President for a two-year term. He succeeds Ian C. Read, Chairman of the Board and Chief Executive Officer, Pfizer. IFPMA also appointed Unjela Kaleem as Director of Communications. // Asceneuron (Lausanne, Switzerland, and Cambridge, MA) announced the appointment of Thomas C. Wessel, MD, PhD, as Chief Medical Officer. // Metafora biosystems (Paris, France), a company developing diagnostic tests to detect abnormalities in cellular energetics, appointed Christophe Béesau as Chief Scientific Officer and Chief Technical Officer. // Nosopharm (Lyon,France) appointed Dr. Sarah Gould as Chief Development Officer. // H. Lundbeck (Valby, Denmark) announced that Anders Gersel Pedersen, Executive Vice President and Head of Research and Development, will retire after 19 years with the company, effective December 31, 2018. // Azeria Therapeutics Limited (Cambridge, UK), a newly formed drug discovery company, announced the appointment of Dr. Julian Blagg as VP Drug Discovery. // Mundipharma (Cambridge, UK) appointed Marco Cerato as Senior Vice President Business Development and Strategic Partnerships. The company also confirmed the appointment of Arnaud Breabout as Senior Vice President & Chief Financial Officer.

update my profile / advertise with us / print subscribe / digital subscribe / visit pharmexec.com